Imatinib Teva
Analogs of Imatinib Teva
Find cheaper analogs and generic equivalents for Imatinib Teva.
Active Ingredient: imatinib
Product Overview
About Imatinib Teva
Imatinib Teva is a cancer medicine.
What it is used for
Imatinib Teva is used to treat the following diseases:
- Chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
- Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly.
- Myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells.
- Advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
- Dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
How it is used
Imatinib Teva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
It is available as capsules (100 and 400 mg) and tablets (100 and 400 mg) and is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
The dose depends on the age and condition of the patient, and the response to treatment, but it should not exceed 800 mg a day.
How it works
The active substance in Imatinib Teva, imatinib, is a protein-tyrosine kinase inhibitor.
This means that it blocks some specific enzymes known as tyrosine kinases.
These enzymes can be found in certain receptors in cancer cells, including the receptors that are involved in stimulating the cells to divide uncontrollably.
By blocking these receptors, Imatinib Teva helps to control cell division.
Active substance: imatinib
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
